Survival curves were weighted by age and sex distributions of the cohort with aspirin use modeled as time dependent. In patients with gallbladder cancer, the survival probabilities were for aspirin users vs nonusers were 59% (95 CI, 31%-100%) vs 27% (95% CI, 16%-47%). The survival probabilities in aspirin users vs nonusers with cholangiocarcinoma were 62% (95% CI, 42%-98%) 26% (95% CI, 19%-35%). In patients with ampulla of Vater cancer, the survival probabilities were 85% (95% CI, 33%-83%) vs 52% (95% CI, 18%-43%) in aspirin users vs nonusers, respectively. Survival probabilities in aspirin users vs nonusers with overlapping lesions of the biliary tract were 57% (95% CI, 34%-100%) vs 27% (95% CI, 16%-46%). Estimated survival at 1 year after diagnosis (dotted line) was calculated with 95% CIs computed based on the quantiles of the corresponding bootstrap distribution function with 1,000 replications. The numbers at risk represent individuals at the beginning of each time point.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Jackson SS, Pfeiffer RM, Liu Z, et al. Association Between Aspirin Use and Biliary Tract Cancer Survival. JAMA Oncol. 2019;5(12):1802–1804. doi:10.1001/jamaoncol.2019.4328
Biliary tract cancers (BTCs) are rare, with a worldwide incidence of less than 2 per 100 000 individuals.1 The 5-year survival rate ranges from 5% to 15%, with a median survival of less than 1 year.1 Between 60% and 70% of patients present with late-stage disease (eg, inoperable or metastatic tumors) owing to the lack of symptoms.2 Consequently, there is a critical need for treatments that improve BTC survival. Aspirin has been proposed as a treatment to reduce cancer mortality because it may slow cancer growth through the inhibition of both cyclooxygenase 2, which promotes inflammation and cell proliferation,3 and platelet aggregation, which may slow the metastatic spread of cancer.4 We investigated the association between postdiagnosis aspirin use and BTC survival.
This study was approved by the National Institutes of Health Human Research Protection Program and the Independent Scientific Advisory Committee of the Clinical Practice Research Datalink ([CPRD] Protocol 17_160.R), and it was deemed exempt from patient written consent requirements because it was conducted using deidentified data. We obtained data, including all-cause deaths, on adult patients diagnosed with BTC from 1990 through 2017 from the United Kingdom’s CPRD, an electronic medical record database. We identified cancers using Read codes for gallbladder cancer (GBC), cholangiocarcinoma, ampulla of Vater cancer (AVC), and overlapping lesions of the biliary tract. We excluded patients with previous cancer, except for nonmelanoma skin cancer.
Ever use of postdiagnosis aspirin was defined as 1 prescription or more recorded in the CPRD on or after the BTC diagnosis date. We used Cox proportional hazards regression models to estimate the cancer site-specific hazard ratios (HRs) and 95% CIs for the association between time–dependent postdiagnosis aspirin use and overall survival. Patients who received an aspirin prescription within 30 days of diagnosis entered the model as users. The time scale began at diagnosis until death, exit from the study, or the end of follow-up (truncated at 10 years). We adjusted for the following covariates a priori: age at diagnosis, sex, comorbidities, statin use at diagnosis, indicators of a healthy lifestyle, and year of diagnosis. We fit separate models for each BTC type and stratified the baseline hazard by prediagnosis aspirin use (yes/no). We estimated adjusted survival curves using a marginal approach to remove the sex and age effects on aspirin use, accounting for the time-dependent exposure.5 We conducted analyses from April to May 2019 using SAS (version 9.4; SAS Institute) and survival curves in R Studio (version 1.1.453).
Among the eligible 2934 patients with BTC, 667 (23%) had GBC; 1559 (53%) cholangiocarcinoma; 224 (8%) AVC; and 484 (16%) overlapping. There were 2415 deaths (82%), with a median survival of 5.8 (interquartile range, 2-15) months. Two-hundred and fifty-six (9%) patients were aspirin users at baseline, with an additional 349 (12%) patients initiating aspirin use after diagnosis. Ninety-six percent of aspirin users (n = 2817) were prescribed a 75-mg dose. Compared with nonusers, aspirin users were more likely to be older, current statin users, and prediagnosis aspirin users and were more likely to have heart disease and comorbidities.
Aspirin use was associated with decreased risk of death in patients with GBC (HR, 0.63; 95% CI, 0.48-0.83), cholangiocarcinoma (HR, 0.71; 95% CI, 0.60-0.85), AVC (HR, 0.44; 95% CI, 0.26-0.76), and overlapping BTC (HR, 0.68; 95% CI, 0.50-0.92) (Table). The survival probabilities are shown in the Figure. Incident users with no history of aspirin use had a larger benefit from postdiagnosis aspirin use than prevalent users, although all users had a reduction in risk of death.
We observed a reduced risk of death for postdiagnosis aspirin users across all BTC types. Platelet activation protects tumor cells from elimination, enhances metastatic cell growth, and enables cancerous cells to spread via the bloodstream.4,6 Aspirin may slow the metastatic spread of cancer cells through inhibition of platelet aggregation, improving BTC survival.1 A limitation of our analysis is the lack of data on cancer stage and chemotherapy regimens received (if any). However, most BTCs are diagnosed at late stage2 with less than 10% of patients presenting with resectable tumors and 50% of tumors metastasizing to the lymph nodes.1 The survival benefit of aspirin observed in our study is on par with the current standard of care.2
Accepted for Publication: August 8, 2019.
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2019 Jackson SS et al. JAMA Oncology.
Published Online: October 17, 2019. doi:10.1001/jamaoncol.2019.4328
Correction: This article was corrected on December 12, 2019, to remove the extra number at risk data from each panel in the Figure.
Corresponding Author: Sarah S. Jackson, PhD, Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 9609 Medical Center Dr, Rockville, MD 20892 (email@example.com).
Author Contributions: Drs Jackson and Koshiol had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Liu, Koshiol.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Jackson, Pfeiffer.
Critical revision of the manuscript for important intellectual content: Liu, Anderson, Gadalla, Koshiol.
Statistical analysis: Jackson, Pfeiffer.
Obtained funding: Koshiol.
Administrative, technical, or material support: Jackson, Liu, Gadalla, Koshiol.
Study supervision: Koshiol.
Conflict of Interest Disclosures: None reported.
Funding/Support: Intramural Research Program of the National Institutes of Health, Division of Cancer Epidemiology and Genetics, National Cancer Institute.
Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Disclaimer: This article reflects the views of the authors and does not necessarily represent US Food and Drug Administration’s views or policies.
Additional Contributions: We thank Bin Zhu, PhD, from the Division of Cancer Epidemiology and Genetics of the National Cancer Institute, for his statistical support in an earlier version of this article. He did not receive compensation for his contributions.